Molecule Details
| InChIKey | OIIOPWHTJZYKIL-PMACEKPBSA-N |
|---|---|
| Canonical SMILES | COc1nc(-c2cccc(-c3cccc(-c4cnc(CNC[C@@H]5CCC(=O)N5)c(OC)n4)c3Cl)c2Cl)cnc1CNC[C@@H]1CCC(=O)N1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 9.67 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB21520 |
|---|---|
| Drug Name | Evixapodlin |
| CAS Number | 2374856-75-2 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Evixapodlin is a small molecule drug. Evixapodlin is under investigation in clinical trial NCT04049617 (Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors). Evixapodlin has a monoisotopic molecular weigh... |
Categories: Immune Checkpoint Inhibitors
Cross-references: BindingDB: 451999 CHEMBL5095237 PDB: A1IZJ
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| Q9NZQ7 | CD274 | Programmed cell death 1 ligand 1 | inhibitor | targets |